Tuesday, February 14th, 2:30pm-3:00pm
John F. Milligan, PhD
President and Chief Operating Officer, Gilead Sciences
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University.
Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
Managing Director, Equity Research Biotechnology, Stifel Nicolaus Weisel
Joel Sendek is a Managing Director and Biotechnology Analyst at Stifel, Nicolaus & Company. He is also Group Head of Healthcare Equity Research at Stifel. He has been a senior biotechnology analyst for 15 years with coverage that spans both large-cap and small-cap companies. Prior to joining Stifel, Joel was a Managing Director and biotechnology analyst for 12 years at Lazard Capital Markets, where he established Lazard’s healthcare equity research effort in 2000. Prior to Lazard he was a Senior Vice President and biotechnology research analyst at Gerard Klauer Mattison. He has been recognized by the Wall Street Journal as an All-Star Analyst with a #1 ranking for stock picking in biotechnology as well as first place in the “Home Run Hitter” category among all sectors.
From 1992 to 1997, Joel served as Senior Director of Corporate Development at Progenics Pharmaceuticals, where he negotiated corporate partnerships, raised private equity capital and prepared the company for an IPO. Prior to Progenics, he worked in the corporate finance department at Goldman, Sachs & Co., focused on healthcare, from 1989 to 1992.
Joel received a Bachelor of Arts in Biochemistry from Rice University.